NCT02675400View on ClinicalTrials.gov

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
DRUG

Vyvanse

Half of the participants (fathers) will be randomized to receive Vyvanse.

BEHAVIORAL

Behavioral Parent Training

Half of the fathers will receive behavioral parent training.

DRUG

Methylphenidate

If Vyvanse is not well tolerated, methylphenidate can be prescribed.

Trial Locations (1)

98105

Seattle Children's, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER

NCT02675400 - Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too) | Biotech Hunter | Biotech Hunter